Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: July 31, 2025
Reporting Period: Second Quarter of 2025
This filing serves as a notification that the Company issued an Earnings Press Release and a presentation regarding its financial results for the second quarter of 2025. The detailed financial data is contained within the exhibits (Exhibit 99.1 and 99.2) incorporated by reference, rather than within the body of this 8-K form.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are disclosed in the Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2), which are referenced but not reproduced in this summary.
Material Changes
No material changes or comparative financial data are detailed in the text of this filing. The document solely announces the availability of the Q2 2025 results.
Guidance, Outlook, and Management Commentary
- Disclosure Method: Management commentary, guidance, and outlook are provided in the Earnings Press Release and the accompanying presentation materials.
- Non-GAAP Measures: The referenced materials include non-GAAP financial information. Reconciliations to GAAP measures are available in the Earnings Press Release.
- Regulation FD: The presentation materials were posted under Regulation FD to ensure fair disclosure during the conference call and webcast.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q2 2025 revenue, net income, and earnings per share figures.
- Examine Exhibit 99.2 (Presentation Materials) for updated full-year guidance and strategic initiatives.
- Verify the reconciliation between non-GAAP and GAAP financial measures provided in the press release.
- Confirm the status of the Celgene Contingent Value Rights (CELG RT) listed as a registered security.